论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
巨噬细胞膜仿生脂质体鼻腔给药靶向递送治疗缺血性中风
Authors Liu T, Zhang M, Zhang J, Kang N, Zheng L, Ding Z
Received 9 January 2024
Accepted for publication 10 June 2024
Published 19 June 2024 Volume 2024:19 Pages 6177—6199
DOI https://doi.org/10.2147/IJN.S458656
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Anderson Oliveira Lobo
Tianshu Liu, Mengfan Zhang, Jin Zhang, Naijin Kang, Linlin Zheng, Zhiying Ding
School of Pharmaceutical Sciences, Jilin University, Changchun, 130021, People’s Republic of China
Correspondence: Zhiying Ding, School of Pharmaceutical Sciences, Jilin University, Changchun, 130021, People’s Republic of China, Tel/Fax +86 13843180286, Email dzy@jlu.edu.cn
Purpose: Ginsenoside Rg3 (Rg3) and Panax notoginseng saponins (PNS) can be used for ischemic stroke treatment, however, the lack of targeting to the ischemic region limits the therapeutic effect. To address this, we leveraged the affinity of macrophage membrane proteins for inflamed brain microvascular endothelial cells to develop a macrophage membrane-cloaked liposome loaded with Rg3 and PNS (MM-Lip-Rg3/PNS), which can precisely target brain lesion region through intranasal administration.
Methods: MM-Lip-Rg3/PNS was prepared by co-extrusion method and was performed by characterization, stability, surface protein, and morphology. The cellular uptake, immune escape ability, and blood-brain barrier crossing ability of MM-Lip-Rg3/PNS were studied in vitro. The in vivo brain targeting, biodistribution and anti-ischemic efficacy of MM-Lip-Rg3/PNS were evaluated in MACO rats, and we determined the diversity of the nasal brain pathway through the olfactory nerve blockade model in rats. Finally, the pharmacokinetics and brain targeting index of MM-Lip-Rg3/PNS were investigated.
Results: Our results indicated that MM-Lip-Rg3/PNS was spherical with a shell-core structure. MM-Lip-Rg3/PNS can avoid mononuclear phagocytosis, actively bind to inflammatory endothelial cells, and have the ability to cross the blood-brain barrier. Moreover, MM-Lip-Rg3/PNS could specifically target ischemic sites, even microglia, increase the cumulative number of drugs in the brain, improve the inflammatory environment of the brain, and reduce the infarct size. By comparing olfactory nerve-blocking rats with normal rats, it was found that there are direct and indirect pathways for nasal entry into the brain. Pharmacokinetics demonstrated that MM-Lip-Rg3/PNS exhibited stronger brain targeting and prolonged drug half-life.
Conclusion: MM-Lip-Rg3/PNS might contribute to the accumulation of Rg3 and PNS in the ischemic brain area to improve treatment efficacy. This biomimetic nano-drug delivery system provides a new and promising strategy for the treatment of ischemic stroke.
Keywords: macrophage-membrane coating, biomimetic liposome, brain targeting, ischemic stroke, intranasal delivery